Yehuda Kolander’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (2)


3D Printing in Orthopedic Oncology
  • Chapter

January 2019

·

46 Reads

·

10 Citations

·

·

Yehuda Kolander

·

Solomon Dadia

Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?

May 2014

·

28 Reads

·

8 Citations

Medical Oncology

I Kushnir

·

Y Kolander

·

J Bickels

·

[...]

·

Neoadjuvant chemotherapy for osteosarcoma is the standard of care, but there is still confusion regarding the best chemotherapy regimen and the optimal intensity. This retrospective study intends to evaluate whether there is a clear correlation between the chemotherapy dose intensity (DI) and the percentage of tumor necrosis, the risk of tumor recurrence after surgery and patient survival. The medical records of all adult patients with localized osteosarcoma that received treatment between the years of 1998 and 2009 at the Tel Aviv Sourasky Medical Center were analyzed. We used multiple logistic/linear regression models to test the effect of the neoadjuvant chemotherapy relative DI (RDI) on histological response, recurrence and time to recurrence. A Cox regression analysis was conducted for the effects of neoadjuvant chemotherapy RDI, histological response, tumor location, gender and age on patient survival. Thirty medical records were analyzed. Survival, histological response, recurrence and time to recurrence were not affected by the chemotherapy RDI. The 5-year overall survival of the patient's population was found to be 63 % with a median survival of 9.4 years. Patients with a good histological response had a longer survival than those with a bad response (mean survival times 11.0 vs. 6.6 years, log-rank test, P = 0.046). High DI is not a prognostic factor in osteosarcoma and maintaining it should not be a prime priority. Histological response is a prognostic but possibly not a reliable predictive factor, and further research is needed in order to find other reliable factors.

Citations (2)


... Furthermore, when tumors are located in proximity to the knee or hip joints, PSIs facilitate joint-sparing surgeries, offering significant functional advantages over joint-sacrificing procedures. 26,[33][34][35]68,[73][74][75][76] To date, limb salvage surgery is the gold standard treatment for tumors surrounding the knee joint. The knee joint is usually sacrificed to maintain a safe negative margin, and a metallic modular endoprosthesis is used for joint arthroplasty and reconstruction. ...

Reference:

Advancements and applications of 3D printing in pediatric orthopedics: A comprehensive review
3D Printing in Orthopedic Oncology
  • Citing Chapter
  • January 2019

... Traditionally, response to chemotherapy was described in terms of tumor necrosis [22]. A study of adult osteosarcoma patients evaluating the efficacy of high-dose chemotherapy confirmed that histological response is an important prognostic factor, as patients with 90% or more tumor necrosis had significantly better overall survival than patients with less tumor necrosis [23]. In a study of patients with extremity osteosarcoma, patients with 90% or more necrosis in their surgical specimens had a five-year survival rate close to 80%, which was significantly longer than patients with a necrosis rate less than 90% [12]. ...

Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?
  • Citing Article
  • May 2014

Medical Oncology